Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last CNY13.57 CNY
Change Today -1.51 / -10.01%
Volume 22.7M
As of 3:00 AM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

jilin zixin pharmaceutical-a (002118) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/11/15 - CNY28.15
52 Week Low
07/7/15 - CNY10.86
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for JILIN ZIXIN PHARMACEUTICAL-A (002118)

Related News

No related news articles were found.

jilin zixin pharmaceutical-a (002118) Related Businessweek News

No Related Businessweek News Found

jilin zixin pharmaceutical-a (002118) Details

Jilin Zixin Pharmaceutical Industrial Co., Ltd researches, develops, manufactures, and sells traditional Chinese patent drugs in China. It is also involved the plantation of medicinal materials. The company provides Huoxue Tongmai tablets, Simiao pills, Fufang Yigan tablets, Xingnao Zaizao capsules, Shen Fukang capsules, Bushen Anshen oral solutions, Liuwei Dihuang capsules, ginseng products, Shexiang Jiegu capsules, and other products. It primarily offers drugs for the treatment of cardiovascular and cerebrovascular diseases, digestive system diseases, and bone fractures. The company is based in Tonghua, China.

jilin zixin pharmaceutical-a (002118) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

jilin zixin pharmaceutical-a (002118) Key Developments

Jilin Zixin Pharmaceutical Industrial Co.,Ltd Announces Earnings Results for the First Half of 2015

Jilin Zixin Pharmaceutical Industrial Co.,Ltd announced earnings results for the first half of 2015. For the period, the company reported net profit of CNY 2.9357 million, representing CNY 0.01 per share, in contrast to net loss of CNY 23.3299 million a year earlier. Operating revenue reached CNY 226 million, declining 27.62%, due to great impact on operating revenue in last reporting period from selling wild ginseng.

Jilin Zixin Pharmaceutical Industrial Co.,Ltd to Report First Half, 2015 Results on Aug 27, 2015

Jilin Zixin Pharmaceutical Industrial Co.,Ltd announced that they will report first half, 2015 results on Aug 27, 2015

Jilin Zixin Pharmaceutical Industrial Co.,Ltd, Special/Extraordinary Shareholders Meeting, Jul 29, 2015

Jilin Zixin Pharmaceutical Industrial Co.,Ltd, Special/Extraordinary Shareholders Meeting, Jul 29, 2015., at 15:00 China Standard Time. Agenda: To consider 2015 1st phase staff shareholding plan (draft) and its summary; and to consider authorization to the board to handle matters in relation to the staff shareholding plan.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
002118:CH CNY13.57 CNY -1.51

002118 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 002118.
View Industry Companies

Industry Analysis


Industry Average

Valuation 002118 Industry Range
Price/Earnings 87.4x
Price/Sales 2.2x
Price/Book 0.8x
Price/Cash Flow 102.4x
TEV/Sales 8.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JILIN ZIXIN PHARMACEUTICAL-A, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at